← Back to headlines
CRISPR Therapeutics Reports $116M FY25 Revenue Driven by CASGEVY Growth
CRISPR Therapeutics announced $116 million in revenue for fiscal year 2025, primarily attributed to the growth of its gene-editing therapy, CASGEVY.
11 Mar, 20:56 — 11 Mar, 20:56
Sources
Showing 1 of 1 sources
Related Stories
Trump Administration Advances Venezuela Oil Talks and Drug Pricing Deals
30m ago
Brookfield Structures $1.8 Billion Bond Deal to Fund $600 Million Dividend
53m ago
Nigeria Reports 4.43 Percent Economic Growth in Second Quarter
57m ago
Prediction Platform Kalshi Permanently Bans George Santos Over Insider Trading
1h ago